Hypermethylation of CDK10 promoter was also confirmed with high frequency (57.5%) of nasopharyngeal carcinomas samples and cell lines and low CDK10 expression is also correlating with advanced TNM stages in HCC samples where its expression could regulate chemosensitivity to cisplatin and epidoxorubicin.392,396. This evidence concerns the gene CDK10 and nasopharyngeal carcinoma.